Details of the Drug

General Information of Drug (ID: DM7C8YV)

Drug Name
Plicamycin
Synonyms A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01
Indication
Disease Entry ICD 11 Status REF
Hypercalcaemia 5B91.0 Approved [1]
Testicular cancer 2C80 Approved [1]
Solid tumour/cancer 2A00-2F9Z Withdrawn from market [2], [1]
Lung cancer 2C25.0 Investigative [3]
Ovarian cancer 2C73 Investigative [3]
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski): 4 Molecular Weight (mw) 1085.1
Topological Polar Surface Area (xlogp) 0.6
Rotatable Bond Count (rotbonds) 15
Hydrogen Bond Donor Count (hbonddonor) 11
Hydrogen Bond Acceptor Count (hbondacc) 24
Chemical Identifiers
Formula
C52H76O24
IUPAC Name
(2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5S,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5R,6R)-4-[(2S,4R,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-8,9-dihydroxy-7-methyl-3,4-dihydro-2H-anthracen-1-one
Canonical SMILES
C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@@H]2C[C@@H](O[C@@H]([C@H]2O)C)OC3=CC4=CC5=C(C(=O)[C@H]([C@@H](C5)[C@@H](C(=O)[C@H]([C@@H](C)O)O)OC)O[C@H]6C[C@H]([C@@H]([C@H](O6)C)O)O[C@H]7C[C@H]([C@H]([C@H](O7)C)O)O[C@H]8C[C@]([C@@H]([C@H](O8)C)O)(C)O)C(=C4C(=C3C)O)O)O)O
InChI
InChI=1S/C52H76O24/c1-18-29(72-34-14-30(43(58)21(4)68-34)73-33-13-28(54)42(57)20(3)67-33)12-26-10-25-11-27(49(66-9)48(63)41(56)19(2)53)50(47(62)39(25)46(61)38(26)40(18)55)76-36-16-31(44(59)23(6)70-36)74-35-15-32(45(60)22(5)69-35)75-37-17-52(8,65)51(64)24(7)71-37/h10,12,19-24,27-28,30-37,41-45,49-51,53-61,64-65H,11,13-17H2,1-9H3/t19-,20-,21-,22-,23-,24-,27+,28-,30-,31-,32-,33+,34+,35+,36+,37+,41+,42-,43-,44-,45+,49+,50+,51-,52+/m1/s1
InChIKey
CFCUWKMKBJTWLW-BKHRDMLASA-N
Cross-matching ID
PubChem CID
163659
ChEBI ID
CHEBI:31856
CAS Number
18378-89-7
DrugBank ID
DB06810
TTD ID
D06EPF
VARIDT ID
DR01174

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
RNA synthesis (hRNA synth) TTX2AYW NOUNIPROTAC Modulator [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Plicamycin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
ABT-492 DMJFD2I Minor Decreased absorption of Plicamycin due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [5]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Plicamycin and Levomilnacipran. Chronic pain [MG30] [6]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Plicamycin and Regorafenib. Colorectal cancer [2B91] [7]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Plicamycin and Vortioxetine. Depression [6A70-6A7Z] [6]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Plicamycin and Apigenin. Discovery agent [N.A.] [8]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Plicamycin and Avapritinib. Gastrointestinal stromal tumour [2B5B] [7]
Teriflunomide DMQ2FKJ Major Additive myelosuppressive effects by the combination of Plicamycin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [9]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Plicamycin and Ibrutinib. Mature B-cell lymphoma [2A85] [10]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Plicamycin and Ponatinib. Mature B-cell lymphoma [2A85] [11]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Plicamycin and Tecfidera. Multiple sclerosis [8A40] [12]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Plicamycin and Siponimod. Multiple sclerosis [8A40] [13]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Plicamycin and Fingolimod. Multiple sclerosis [8A40] [14]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Plicamycin and Ozanimod. Multiple sclerosis [8A40] [7]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Plicamycin when combined with Anthrax vaccine. Sepsis [1G40-1G41] [15]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Plicamycin and Brilinta. Thrombosis [DB61-GB90] [7]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Plicamycin and Cabozantinib. Thyroid cancer [2D10] [16]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Plicamycin and Betrixaban. Venous thromboembolism [BD72] [17]
⏷ Show the Full List of 17 DDI Information of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8394).
3 The Pluripotency Factor Musashi-2 Is a Novel Target for Lung Cancer Therapy.Ann Am Thorac Soc. 2018 Apr;15(Supplement_2):S124.
4 Role of magnesium ion in mithramycin-DNA interaction: binding of mithramycin-Mg2+ complexes with DNA. Biochemistry. 1995 Jan 31;34(4):1376-85.
5 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
6 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
7 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
8 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
9 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
10 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
11 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
12 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
13 Cerner Multum, Inc. "Australian Product Information.".
14 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
15 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
16 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
17 Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3. [PMID: 27489634]